SCHEMBL394991

SCHEMBL394991

FC(F)(F)c1cccc(Nc2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 5/20 0.70
▸ IDH2 P48735 3/20 0.67
▸ MAPT P10636 4/20 0.65
▸ ALDH1A1 P00352 2/20 0.65
▸ GAA P10253 2/20 0.65
▸ RAB9A P51151 2/20 0.65
▸ RAPGEF4 Q8WZA2 1/20 0.65
▸ SMN1; SMN2 Q16637 1/20 0.65
▸ NPSR1 Q6W5P4 1/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ AURKA O14965 1/20 0.57
▸ THRB P10828 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ MEN1 O00255 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ AKR1C3 P42330 1/20 0.56
▸ AKR1C2 P52895 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1921482 0.96 KIF11 (0.70) KIF11IDH2MAPTALDH1A1GAA
SCHEMBL30575363 0.94 IDH2 (0.77) KIF11IDH2MAPTALDH1A1GAA
SCHEMBL7347670 0.94 IDH2 (0.77) KIF11IDH2MAPTALDH1A1GAA
SCHEMBL1921505 0.90 KIF11 (0.64) KIF11IDH2MAPTALDH1A1GAA
SCHEMBL9070348 0.88 RAPGEF4 (0.68) KIF11IDH2MAPTALDH1A1GAA
SCHEMBL27747543 0.88 MPO (0.58) KIF11IDH2MAPTALDH1A1GAA
SCHEMBL1921484 0.87 MAPT (0.77) KIF11IDH2MAPTALDH1A1GAA
SCHEMBL16411339 0.87 KIF11 (0.65) KIF11IDH2MAPTALDH1A1GAA
SCHEMBL5543915 0.87 IDH2 (0.58) KIF11IDH2MAPTALDH1A1GAA
SCHEMBL10568041 0.87 KIF11 (0.71) KIF11IDH2MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product ASAHI KASEI KABUSHIKI KAISHA (JP) 2026-03-17 — — US disclosed
US-20230135772-A1 CARBODIIMIDE COMPOSITION, CURING AGENT COMPOSITION, COATING COMPOSITION AND RESIN CURED PRODUCT ASAHI KASEI KABUSHIKI KAISHA (JP) 2023-05-04 — — US disclosed
EP-4130154-A1 CARBODIIMIDE COMPOSITION, HARDENER COMPOSITION, COATING COMPOSITION, AND CURED RESIN OBJECT Asahi Kasei Kabushiki Kaisha (JP) 2023-02-08 — — EP disclosed
US-9695260-B2 Method for producing olefin block polymer using plurality of types of transition metal catalysts SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-07-04 — — US disclosed
EP-1867623-B1 TERPHENYLENE DERIVATIVES, TETRAHALOTERPHENYL DERIVATIVES AND PROCESSES FOR THE PRODUCTION OF BOTH TOSOH CORP (JP) 2017-05-10 — — EP disclosed
US-9593194-B2 Method for producing olefin block polymer using group 4 transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-03-14 — — US disclosed
US-9200093-B2 Polymerization method using surfactant-containing particle SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-12-01 — — US disclosed
US-8871885-B2 Ethylene-a-olefin copolymer and molded article SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-10-28 — — US disclosed
US-20140288251-A1 POLYMERIZATION METHOD USING SURFACTANT-CONTAINING PARTICLE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-25 — — US disclosed
US-20140275429-A1 METHOD FOR PRODUCING OLEFIN BLOCK POLYMER USING PLURALITY OF TYPES OF TRANSITION METAL CATALYSTS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-18 — — US disclosed
US-20020143124-A1 Homogeneous type solid catalyst component or homogeneous type solid catalyst, process for production thereof and process for producing addition polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-10-03 — — US disclosed
US-6346621-B1 INDOLE OR QUINOLINE COMPOUNDS SUBSTITUTED WITH AMINO COMPOUNDS ON NITROGEN TOSOH CORPORATION (JP) 2002-02-12 — — US disclosed
EP-1153938-A1 CATALYST FOR STEREOREGULAR POLYMERIZATION OF ALPHA-OLEFIN AND PROCESS FOR PRODUCING STEREOREGULAR ALPHA-OLEFIN POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-11-14 — — EP disclosed
US-20010020075-A1 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-09-06 — — US disclosed
US-6284699-B1 COORDINATION POLYMERIZATION CATALYSTS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-09-04 — — US disclosed
EP-1114832-A1 Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-11 — — EP disclosed
US-20010007007-A1 Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-05 — — US disclosed
EP-1113026-A2 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-04 — — EP disclosed
EP-1035114-A2 Nitrogen-heterocyclic compounds and process for production thereof TOSOH CORPORATION (JP) 2000-09-13 — — EP disclosed
EP-0949273-A1 MODIFIED PARTICLES, CARRIER PREPARED THEREFROM, OLEFIN POLYMERIZATION CATALYST COMPONENT PREPARED THEREFROM, OLEFIN POLYMERIZATION CATALYST PREPARED THEREFROM, AND PROCESS FOR PREPARING OLEFIN POLYMER Sumitomo Chemical Company, Limited (JP) 1999-10-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product CD38, PARP9, MCCC2 KIF11 3858/4885IDH2 3117/4885MAPT 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback